To the Editor:
Recent scientific evidence has indicated that inflammation plays a fundamental role in all stages of atherosclerosis. Many reports contend that atherosclerosis could represent a chronic phlogistic disorder and its exacerbations could determine acute cardiovascular and cerebrovascular events. C-reactive protein (CRP) is the prototype of the acute phase of inflammation, so it is used as a biochemical marker in the studies demonstrating the relationship between inflammation and atherosclerosis in all its manifestations, both cardiovascular and cerebrovascular (1, 3) . Few data refer to the relation between the acute phase of inflammation, especially for CRP, and venous thromboembolic disease (VTD). In a prospective study, CRP, fibrinogen, and white blood cell (WBC) count were not associated with risk of venous thromboembolism in healthy subjects during a mean follow-up of about 8 years (4). Moreover, no association between CRP polymorphism/haplotypes and the risk of thromboembolism was observed (5) . In another study, CRP did not provide additional information about the diagnosis of deep vein thrombosis and differential diagnosis with inflammatory diseases (6) , while in another one it was demonstrated that CRP increases in the first day of admission for deep venous thrombosis (DVT) with a decline in the next days, demonstrating that inflammation could be the result of DVT rather than the cause (7) . Steeghs and colleagues conclude that CRP could be used alone or combined with a model of pre-test clinical probability to safely exclude pulmonary embolism (PE) (8) . In disagreement with these results, Aujesky and colleagues in a previous study had concluded that CRP cannot safely exclude PE when used alone or in combination with clinical probability assessment in suspected PE compared to D-Dimer assay (9) .
We present the results of our study to evaluate the role of the acute phase of inflammation in elderly patients with suspected and confirmed PE. Of 118 patients admitted in our acute geriatric ward who underwent perfusion lung scan for suspected PE according to PISA-PED criteria (10), 69 females and 49 males, with mean age 77.76 ± 7.17 years, with absence of PE (43 patients, 20 females and 23 males, named in the study unconfirmed PE group, UCPE) and with high probability for PE (75 patients, 49 females and 26 males, named confirmed PE group, CPE), we retrospectively analyzed the following laboratory parameters, performed within 24 hours from hospital admission: CRP (Dade/Behring Diagnostics, Marburg, Germany, sensitivity 0.0175 mg/dL, specificity 100%), WBC count, erythrocyte sedimentation rate (ESR), fibrinogen levels (Multifibren, Dade/Behring Diagnostics, Marburg, Germany, sensitivity 80-1200 mg/dL, variability coefficient 1.5%-5%,), D-Dimer levels (IL Test D-Dimer quantitative method, ACL Futura, Instrumentation Laboratory, Biokit S.A., Barcelona, Spain, cut-off 500 ng/mL), and arterial blood gas analysis parameters (BGA/Electrolytes, IL Instrumentation Laboratory, Milan, Italy). We compared markers of acute phase of inflammation between UCPE and CPE groups and in the CPE group we analyzed these markers in massive, submassive, and non-massive PE and finally compared these between survivors (54 patients) and those who died (21 patients). Main diagnoses of the UCPE group were heart failure, 40%; ischemic heart disease, 26%; exacerbation of chronic obstructive pulmonary disease, 24%; arrhythmias, 14%; pneumonia, 10%; and syncope, 10%. Table  1 summarizes the results of our study. CRP was significantly higher in the UCPE group, while D-Dimer was higher in the CPE group. We didn't find differences for the other markers of inflammation between the two groups. In UCPE, 20 patients (46.5%) had CRP values 1 mg/dL or less, 12 (27.9%) had values from 1 to 5 mg/dL, and 11 (25.6%) had values greater than 5 mg/dL. In the CPE group, 33% of patients had values 1 mg/dL or less, 42.6% had values from 1 to 5 mg/dL, and 24.4% had values greater than 5 mg/dL.
In the CPE group, WBC count and fibrinogen were higher in massive PE, whereas CRP and D-Dimer were higher in non-massive PE. Moreover WBC and D-Dimer count were significantly higher in patients who died, while CRP and ESR were higher in survivors. Table 2 shows the risk factors for PE in the CPE group. One third of patients (25 of 75, 33%) have three or more risk factors.
Diagnosis and prognostic stratification of PE in the elderly are important topics. In the diag- nosis of PE in the elderly, many doubts exist (11) . One of the most important doubts is the role of D-Dimer: few elderly patients in fact have D-Dimer below a cut-off of 500 ng/mL, value by which it should be safely possible to exclude PE in clinical low probability pre-test patients. This observation has induced Righini and colleagues (12) to propose the exclusion of D-Dimer in diagnostic strategies for PE in the elderly. CRP could be an interesting alternative, but in the elderly comorbidity could reduce its role in the diagnostic field. In this study, we noticed that mean CRP values were higher in patients without PE, although a greater percentage of UCPE patients had values of CRP below 1 mg/dL (46.5% vs 33%). Moreover, we have found that CRP values could have no role in terms of assessing severity of PE and prognosis.
In conclusion, our study demonstrates the absence of a role of the acute phase of inflammation in suspected PE and could be one of the first citations in the literature about the absence of a role of acute phase of inflammation in the prognosis of PE. Further prospective studies should be addressed to clarify these results. 
